According to TipRanks.com, Yang is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of -2.7% and a 39.2% success rate. Yang covers the Healthcare sector, focusing on stocks such as Xeris Pharmaceuticals, Magenta Therapeutics, and Nektar Therapeutics.
Currently, the analyst consensus on Sarepta Therapeutics is a Moderate Buy with an average price target of $128.64.
See today’s analyst top recommended stocks >>
The company has a one-year high of $181.83 and a one-year low of $77.01. Currently, Sarepta Therapeutics has an average volume of 1.97M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which is engaged in the discovery and development of therapeutics for the treatment of rare diseases. The company was founded on July 22, 1980 and is headquartered in Cambridge, MA.